These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22456295)

  • 1. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
    Young A; Anzures-Cabrera J; Derks M
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):248-56. PubMed ID: 22456295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
    Coates PE; Mesure R
    Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study.
    Johnson-Agbakwu C; Brown L; Yuan J; Kissling R; Greenblatt DJ
    Clin Ther; 2018 Jan; 40(1):64-73. PubMed ID: 29198449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
    Vonk MC; Guillén-Del-Castillo A; Kreuter M; Avis M; Marzin K; Mack SR; Wind S; Gahlemann M
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):81-89. PubMed ID: 34664183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
    Cawello W; Rosenkranz B; Schmid B; Wierich W
    Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of avosentan (SPP3OI) on the pharmacokinetics of a second generation oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
    Dieterle W; Mann J
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):668-74. PubMed ID: 17190377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
    Kuhnz W; al-Yacoub G; Fuhrmeister A
    Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women.
    Stockis A; Rolan P
    J Clin Pharmacol; 2013 Dec; 53(12):1313-21. PubMed ID: 24386664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
    Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
    Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive.
    Braun M; Elshoff JP; Andreas JO; Müller LI; Horstmann R
    Br J Clin Pharmacol; 2009 Sep; 68(3):386-94. PubMed ID: 19740396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
    Sivasubramanian R; Chakraborty A; Rouzade-Dominguez ML; Neelakantham S; Jakab A; Mensinga T; Legangneux E; Woessner R; Ufer M
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):550-6. PubMed ID: 25943176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
    David OJ; Ocwieja M; Meiser K; Emotte C; Jakab A; Wemer J; den Daas I; Schmouder R
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):540-4. PubMed ID: 22735460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
    Kothare PA; Seger ME; Northrup J; Mace K; Mitchell MI; Linnebjerg H
    BMC Clin Pharmacol; 2012 Mar; 12():8. PubMed ID: 22429273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.
    Menon S; Riese R; Wang R; Alvey CW; Shi H; Petit W; Krishnaswami S
    Clin Pharmacol Drug Dev; 2016 Sep; 5(5):336-42. PubMed ID: 27138968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects.
    Mohamed MF; Trueman S; Feng T; Friedman A; Othman AA
    J Clin Pharmacol; 2019 Apr; 59(4):510-516. PubMed ID: 30500075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women.
    Trezza C; Ford SL; Gould E; Lou Y; Huang C; Ritter JM; Buchanan AM; Spreen W; Patel P
    Br J Clin Pharmacol; 2017 Jul; 83(7):1499-1505. PubMed ID: 28087972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
    Elgart A; Zur AA; Mimrod D; Dror V; Bar-Ilan O; Korver T; Spiegelstein O
    Eur J Clin Pharmacol; 2019 Jan; 75(1):41-49. PubMed ID: 30191262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
    Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
    J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
    DiLiberti CE; O'Leary CM; Hendy CH; Waters DH; Margolis MB
    Contraception; 2011 Jan; 83(1):55-61. PubMed ID: 21134504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.